Wednesday, March 23, 2022 MA36 OlympiA trial: Olaparib (Lynparza) as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer Breast International Group (BIG) has announced that the second interim analysis of OlympiA trial building on the earlier published results (NEJM) will lead to fewer deaths among patients with germline BRCA-mutated (gBRCA) breast cancer, as the U.S. Food and Drug Administration announced last Friday approval of olaparib for gBRCA breast cancer patients who have had chemotherapy. The full details of the data were presented yesterday by Prof Andrew Tutt during an ESMO Virtual Plenary session and the study partners issued a joint press release. OlympiA is a global clinical trial that enrolled a total of 1,836 patients from over 600 hospitals and cancer centres in 23 countries worldwide. The study is coordinated by the Breast International Group (BIG), in partnership with NRG Oncology, the US National Cancer Institute (NCI), Frontier Science & Technology Research Foundation (FSTRF), AstraZeneca and MSD. The trial is sponsored by NRG Oncology in the US and by AstraZeneca outside the US and sponsored by CCTG in Canada. We are grateful to all patients who participated in the study and make research and progress possible. And, of course, we’d like to thank all study partners, PIs, researchers, doctors and nurses involved for their commitment and efforts to find better treatments for our patients.
